Ignite Creation Date:
2025-12-24 @ 4:36 PM
Ignite Modification Date:
2026-01-13 @ 11:12 PM
Study NCT ID:
NCT03108066
Status:
COMPLETED
Last Update Posted:
2024-09-24
First Post:
2017-03-28
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)
Sponsor:
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-04-24
Start Date Type:
ACTUAL
Primary Completion Date:
2023-08-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-09-27
Completion Date Type:
ACTUAL
First Submit Date:
2017-03-28
First Submit QC Date:
None
Study First Post Date:
2017-04-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-08-28
Results First Submit QC Date:
None
Results First Post Date:
2024-09-24
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-28
Last Update Post Date:
2024-09-24
Last Update Post Date Type:
ACTUAL